[go: up one dir, main page]

WO1996000503B1 - Nouveaux peptides - Google Patents

Nouveaux peptides

Info

Publication number
WO1996000503B1
WO1996000503B1 PCT/US1995/008156 US9508156W WO9600503B1 WO 1996000503 B1 WO1996000503 B1 WO 1996000503B1 US 9508156 W US9508156 W US 9508156W WO 9600503 B1 WO9600503 B1 WO 9600503B1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
ser
sequence
amino acids
oligopeptides
Prior art date
Application number
PCT/US1995/008156
Other languages
English (en)
Other versions
WO1996000503A1 (fr
Filing date
Publication date
Priority claimed from US08/267,092 external-priority patent/US5599686A/en
Priority to FI965225A priority Critical patent/FI965225A7/fi
Priority to AU30922/95A priority patent/AU689934B2/en
Priority to MX9700043A priority patent/MX9700043A/es
Priority to HU9603564A priority patent/HU220877B1/hu
Priority to EP95926602A priority patent/EP0771209B1/fr
Priority to PL95317872A priority patent/PL186341B1/pl
Priority to NZ290239A priority patent/NZ290239A/en
Priority to BR9508151A priority patent/BR9508151A/pt
Priority to DK95926602T priority patent/DK0771209T3/da
Application filed filed Critical
Priority to JP8503422A priority patent/JPH10502619A/ja
Priority to HK98109815.7A priority patent/HK1009038B/en
Priority to RO96-02483A priority patent/RO116198B1/ro
Priority to DE69528064T priority patent/DE69528064T2/de
Priority to SK1640-96A priority patent/SK164096A3/sk
Priority to AT95926602T priority patent/ATE223224T1/de
Priority to UA97010353A priority patent/UA55371C2/uk
Publication of WO1996000503A1 publication Critical patent/WO1996000503A1/fr
Publication of WO1996000503B1 publication Critical patent/WO1996000503B1/fr
Priority to NO965592A priority patent/NO965592L/no
Priority to BG101077A priority patent/BG63453B1/bg

Links

Abstract

L'invention concerne des oligopeptides comprenant des séquences d'acides aminés reconnues et clivées protéolytiquement par un antigène spécifique de la prostate (PSA). L'invention concerne également des dosages comprenant ces oligopeptides utiles pour déterminer l'activité de la protéase de PSA libre in vitro et in vivo. En outre, l'invention concerne des agents thérapeutiques comprenant des conjugués de ces oligopeptides ainsi que des agents cytotoxiques connus.
PCT/US1995/008156 1994-06-28 1995-06-07 Nouveaux peptides WO1996000503A1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
AT95926602T ATE223224T1 (de) 1994-06-28 1995-06-07 Neuartige peptide
JP8503422A JPH10502619A (ja) 1994-06-28 1995-06-07 新規ペプチド
MX9700043A MX9700043A (es) 1994-06-28 1995-06-07 Peptidos novedosos.
HU9603564A HU220877B1 (en) 1994-06-28 1995-06-07 Novel olygopeptides, diagnostic methods for use thereof and conjugates for treatment of prostata cancer
EP95926602A EP0771209B1 (fr) 1994-06-28 1995-06-07 Nouveaux peptides
PL95317872A PL186341B1 (pl) 1994-06-28 1995-06-07 Oligopeptyd, sposób oznaczania aktywności proteolitycznej wolnego antygenu swoistego dla prostaty wpróbce, sposób identyfikacji związków, hamującychaktywność proteolityczną antygenu swoistego dla prostaty, oraz koniugat użyteczny do leczenia raka prostaty
NZ290239A NZ290239A (en) 1994-06-28 1995-06-07 Peptides, oligopeptides with amino acid sequences that are recognised and proteolytically cleaved by free prostate specific antigen, assays and medicaments comprising such peptides
BR9508151A BR9508151A (pt) 1994-06-28 1995-06-07 Oligopeptídeo testes para determinar a atividade proteolítica de antígeno livre específico para próstata em uma amostra e para identificar compostos que inibem atividade proteolítica de antígeno específico para próstata e conjugado
DK95926602T DK0771209T3 (da) 1994-06-28 1995-06-07 Hidtil ukendte peptider
FI965225A FI965225A7 (fi) 1994-06-28 1995-06-07 Uusia peptidejä
RO96-02483A RO116198B1 (ro) 1994-06-28 1995-06-07 Oligopeptida si conjugat al acesteia, clivate selectiv de antigenul specific de prostata
AU30922/95A AU689934B2 (en) 1994-06-28 1995-06-07 Novel peptides
HK98109815.7A HK1009038B (en) 1994-06-28 1995-06-07 Novel peptides
DE69528064T DE69528064T2 (de) 1994-06-28 1995-06-07 Neuartige peptide
SK1640-96A SK164096A3 (en) 1994-06-28 1995-06-07 Oligopeptide and a conjugate containing it
UA97010353A UA55371C2 (uk) 1994-06-28 1995-07-06 Олігопептид, який розпізнається та протеолітично розщеплюється вільним простатичним антигеном, спосіб визначення протеолітичної активності вказаного антигену, спосіб ідентифікації сполук, які інгібують протеолітичну активність вказаного антигену, кон'югат, який використовують для лікування раку передміхурової залози
NO965592A NO965592L (no) 1994-06-28 1996-12-27 Nye peptider
BG101077A BG63453B1 (bg) 1994-06-28 1996-12-27 Пептиди

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/267,092 US5599686A (en) 1994-06-28 1994-06-28 Peptides
US40483395A 1995-03-15 1995-03-15
US404,833 1995-03-15
US267,092 1995-03-15

Publications (2)

Publication Number Publication Date
WO1996000503A1 WO1996000503A1 (fr) 1996-01-11
WO1996000503B1 true WO1996000503B1 (fr) 1996-02-22

Family

ID=26952210

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/008156 WO1996000503A1 (fr) 1994-06-28 1995-06-07 Nouveaux peptides

Country Status (26)

Country Link
US (1) US6143864A (fr)
EP (1) EP0771209B1 (fr)
JP (1) JPH10502619A (fr)
KR (1) KR100379351B1 (fr)
CN (1) CN1156964A (fr)
AT (1) ATE223224T1 (fr)
AU (1) AU689934B2 (fr)
BG (1) BG63453B1 (fr)
BR (1) BR9508151A (fr)
CA (1) CA2192957A1 (fr)
CZ (1) CZ381096A3 (fr)
DE (1) DE69528064T2 (fr)
DK (1) DK0771209T3 (fr)
ES (1) ES2182908T3 (fr)
FI (1) FI965225A7 (fr)
HU (1) HU220877B1 (fr)
MX (1) MX9700043A (fr)
NO (1) NO965592L (fr)
NZ (1) NZ290239A (fr)
PL (1) PL186341B1 (fr)
PT (1) PT771209E (fr)
RO (1) RO116198B1 (fr)
RU (1) RU2162855C2 (fr)
SK (1) SK164096A3 (fr)
UA (1) UA55371C2 (fr)
WO (1) WO1996000503A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502037A (en) * 1993-07-09 1996-03-26 Neuromed Technologies, Inc. Pro-cytotoxic drug conjugates for anticancer therapy
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
EP1880737A1 (fr) * 1994-08-19 2008-01-23 La Region Wallonne Composés, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation
WO1997014416A1 (fr) * 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugues utiles pour traiter l'adenome prostatique benin
US5952294A (en) * 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
CA2271291A1 (fr) 1996-11-06 1998-05-14 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Proproteines similaires a l'exotoxine de pseudomonas, pouvant etre activees par une protease
AU7582298A (en) 1997-05-19 1998-12-11 Johns Hopkins University School Of Medicine, The Tissue specific prodrug
US6545131B1 (en) 1997-05-19 2003-04-08 The Johns Hopkins University Tissue specific prodrug
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
US6391305B1 (en) * 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
TR200002260T2 (tr) * 1997-12-02 2000-12-21 Merck & Co., Inc. Prostat kanserinin tedavisinde yararlı konjugatlar
WO1999044628A1 (fr) * 1998-03-05 1999-09-10 Merck & Co., Inc. Conjugues convenant au traitement du cancer de la prostate
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US7425541B2 (en) 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
BR0010700A (pt) * 1999-04-30 2002-02-13 Slil Biomedical Corp Conjugados análogos de poliamina e conjugados de quinona como terapias para cânceres e doenças na próstata
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6649587B1 (en) 1999-04-30 2003-11-18 Slil Biomedical Corporation Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
DE60032784T2 (de) * 1999-10-07 2007-11-08 Ciphergen Biosystems, Inc., Fremont Markerproteine für prostatakrebs
GB9924759D0 (en) 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
PL360826A1 (en) 2000-03-15 2004-09-20 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
AU6685301A (en) * 2000-06-14 2001-12-24 Corixa Corp Prodrug compounds with isoleucine
EP1337504A4 (fr) 2000-11-08 2005-10-05 Cellgate Inc Nouveaux conjugues d'acide amine et d'analogues de polyamine utiles en tant qu'agents anticancer
EP1219634A1 (fr) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Glycoconjugués d'agents cytostatiques avec lien peptidique spécifiquement clivable
WO2002081630A2 (fr) * 2001-04-06 2002-10-17 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Utilisation de semenogeline dans le diagnostic, le pronostic et le traitement du cancer
CA2457903C (fr) * 2001-08-24 2018-04-17 University Of Victoria Innovation And Development Corporation Proaerolysine contenant des sequences d'activation de protease et procedes destines au traitement du cancer de la prostate
JP2005510240A (ja) * 2001-11-28 2005-04-21 セローノ ジェネティクス インスティテュート ソシエテ アノニム ヒトｃＤＮＡ及びタンパク質及びその使用
US7108976B2 (en) * 2002-06-17 2006-09-19 Affymetrix, Inc. Complexity management of genomic DNA by locus specific amplification
MXPA05004504A (es) * 2002-10-31 2005-08-16 Metabasis Therapeutics Inc Nuevos di-esteres de fosfato ciclicos de 1,3-propano-1-aril-dioles y su uso en la preparacion de profarmacos.
WO2005041981A1 (fr) * 2003-10-31 2005-05-12 Kurume University Traitement combine vaccin peptidique et estramustine
WO2006133553A1 (fr) 2005-06-14 2006-12-21 Protox Therapeutics Incorporated Méthode pour traiter ou prévenir l’hyperplasie bénigne de la prostate au moyen de protéines formatrices de pores modifiées
JP5278873B2 (ja) * 2008-05-14 2013-09-04 国立大学法人九州工業大学 癌診断用試薬
WO2010117768A1 (fr) * 2009-04-10 2010-10-14 The Regents Of The University Of California Antigènes associés à la prostatite et leurs méthodes d'utilisation
KR20110069618A (ko) * 2009-12-17 2011-06-23 주식회사 셀앤바이오 전립선암 진단용 키트 및 진단방법
US10449210B2 (en) 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
EP3164136A4 (fr) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Composés de promédicaments et leurs utilisations
EP3737676B1 (fr) 2018-01-09 2024-03-06 Ligand Pharmaceuticals, Inc. Composés acétal et leurs utilisations thérapeutiques

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4277466A (en) * 1978-08-29 1981-07-07 Institut International De Pathologie Cellulaire Et Moleculaire Complexes of DNA and esters derived from daunorubicine, their preparation and use
US4446122A (en) * 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
OA06421A (fr) * 1980-06-10 1981-09-30 Omnium Chimique Sa Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides.
EP0124502B1 (fr) * 1983-04-29 1991-06-12 OMNICHEM Société anonyme Nouveaux conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques contenant ces conjugués
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
EP0126344A2 (fr) * 1983-05-20 1984-11-28 Abbott Laboratories Esters tripeptidiques d'agents thérapeutiques
FR2583983B1 (fr) * 1985-06-07 1988-05-27 Centre Nat Rech Scient Nouvelles prodrogues macromoleculaires hydrosolubles, leur preparation et leur utilisation comme medicaments notamment antitumoraux et antiparasitaires
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5220001A (en) * 1989-10-25 1993-06-15 Zaidan Hojim Biseibutsu Dong-A Pharm Co. Anthracycline glycoside derivatives
IT1241927B (it) * 1990-05-14 1994-02-01 Menarini Farma Ind 3'-deamino-4'-deossi-4'-amino-8-fluoroantra- cicline processi per la loro preparazione e composizioni farmaceutiche che le contengono
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
EP0671412A1 (fr) * 1990-11-30 1995-09-13 Asahi Glass Company Ltd. Peptides inhibant l'infiltration de cellules tumorales et inhibiteurs de la métastase du cancer
FR2678274A1 (fr) * 1991-06-25 1992-12-31 Medgenix Group Sa N-leucyl epirubicine application a titre de medicament antitumoral et procede de preparation.
US5288612A (en) * 1991-07-03 1994-02-22 The Scripps Research Institute Assay methods for detecting serum proteases, particularly activated protein C
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE4233152A1 (de) * 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
PT667920E (pt) * 1992-10-29 2003-06-30 Univ Jefferson Metodos de deteccao de micrometasteses do cancro da prostata
WO1994020114A1 (fr) * 1993-03-12 1994-09-15 Board Of Regents, The University Of Texas System Anthracyclines ayant une action inhabituellement forte contre les cellules resistant a la doxorubicine et a ses analogues
GB9320191D0 (en) * 1993-09-30 1993-11-17 Univ Napier Compounds
JPH10500294A (ja) * 1994-05-10 1998-01-13 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 組換え型ｈｋ２ポリペプチド
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
EP1880737A1 (fr) * 1994-08-19 2008-01-23 La Region Wallonne Composés, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation
AUPM769394A0 (en) * 1994-08-25 1994-09-15 Commonwealth Scientific And Industrial Research Organisation Assay for the detection of proteases

Similar Documents

Publication Publication Date Title
WO1996000503B1 (fr) Nouveaux peptides
PL317872A1 (en) Novel peptides
EP0591524A4 (fr)
Mentlein Proline residues in the maturation and degradation of peptide hormones and neuropeptides
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
NZ232742A (en) Yeast heterologous protein production method, vectors, dna constructs and proteins so produced and aprotinin (1-58) so produced
WO1997028247A3 (fr) PROTEINES DE RESERVE DE PLANTES ENRICHIES EN ACIDES AMINES, NOTAMMENT η-ZEINE DE MAIS ENRICHIE EN LYSINE, PLANTES EXPRIMANT CES PROTEINES
EP1623994A3 (fr) Protection de peptides thérapeutiques endogènes contre l'activité peptidase par conjugaison de composants sanguins
EP0150126A3 (en) The synthesis of protein with an identification peptide
DE69109109D1 (de) Ubiquitinspezifische protease.
AU1353295A (en) Peptides derived from a retrovirus of the HIV group, and their use
AU1003888A (en) Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host, process, expression vector and recombinant host therefore and pharmaceutical use thereof
Angliker Synthesis of tight binding inhibitors and their action on the proprotein-processing enzyme furin
De Camargo et al. Influence of the carboxyl terminus of luteinizing hormone-releasing hormone and bradykinin on hydrolysis by brain endo-oligopeptidases.
EP0528686B8 (fr) Procédé pour la production de peptides
AU6710998A (en) Process for preparing modified proteins
AU3850997A (en) Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines
Yonezawa et al. Substrate specificity of cucumisin on synthetic peptides
Bányai et al. Proximity of the catalytic region and the kringle 2 domain in the closed conformer of plasminogen
Levy et al. The digestion of the oxidized B chain of insulin by human neutrophile proteases: elastase and chymotrypsin-like protease
AU9083791A (en) Thrombolytic peptide, production thereof and thrombolytic agent
ATE283914T1 (de) Iga1-protease fragment als trägerpeptid
Nörenberg et al. Processing of the oxytocin precursor: isolation of an exopeptidase from neurosecretory granules of bovine pituitaries
Uddin et al. Specific cleavage of synthetic renin substrate by mouse γ-nerve growth factor
Bächle Cathepsin D: design and characterisation of new in vitro and in vivo substrates applied to biological samples